An Edmonton-based company is appealing the $303,769 fine it was issued for failing to remediate a toxic leak at an oilfield disposal well in central Alberta for more than two years.

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales  Zacks Investment Research

SRPT earnings call for the period ending December 31, 2024. Image source: The Motley Fool. Sarepta Therapeutics (SRPT -0.08%)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call. As a reminder, today's program is being recorded.

Sarepta Therapeutics investors have an opportunity to join a class action lawsuit over alleged securities fraud related to its gene therapy product.

Despite the risks of gene therapy, “we chose the risk of action over reticence,” write two Duchenne mothers.

Sarepta to axe 500 jobs after Elevidys liver failure deaths  FirstWord Pharma

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy.

Sarepta Therapeutics said it won't comply with an FDA request to stop shipping the company's treatment for Duchenne muscular dystrophy, following two patient deaths, likely setting up a high-profile battle with the agency over the ...

Why Sarepta may not survive its current gene therapy crisis  statnews.com

Sarepta Therapeutics (NASDAQ:SRPT) received a negative opinion from the European Medicines Agency's CHMP regarding the conditional marketing authorization for ELEVIDYS in treating Duchenne muscular dystrophy (DMD) patients aged 3-7 years in the EU.While ELEVIDYS, the first gene therapy targeting DMD's underlying cause, has gained approval in the US and other countries since June 2023, Sarepta acknowledges current FDA safety inquiries. Despite not meeting the primary endpoint in the EMBARK study's first year, the therapy demonstrated statistically significant improvements in secondary endpoints. The company submitted additional efficacy data, including two-year EMBARK results and a three-year pooled analysis showing improvements in motor function.Partner Roche will continue discussions with EMA to explore potential pathways for making ELEVIDYS available in the EU, while maintaining responsibility for regulatory approvals outside the US.

Faruqi & Faruqi, LLP is alerting investors in Sarepta Therapeutics about a pending class action lawsuit with a significant deadline approaching. Act now!

Sarepta slides after FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ)  Seeking Alpha

Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns  GuruFocus

Investors in Sarepta Therapeutics, Inc. can lead a class action lawsuit following significant losses related to securities. Deadline is August 25, 2025.

CAMBRIDGE, Mass., November 14, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,